Drug General Information
Drug ID	D0K4PN
Former ID	DIB012131
Drug Name	AZD-1134
Drug Type	Small molecular drug
Indication	Anxiety disorder [ICD9: 300, 311; ICD10:F32, F40-F42]		Terminated	[547616]
Company	AstraZeneca plc
Structure		Download 2D MOL 3D MOL
Formula	C28H32FN5O4
Canonical SMILES	c12oc(cc(=O)c1cc(cc2N1CCN(CC1)C)F)C(=O)Nc1ccc(N2CCN(C(=<br />O)CC)CC2)cc1
CAS Number	CAS 442548-99-4
PubChem Compound ID	9830790
Target and Pathway
Target(s)	5-hydroxytryptamine 1B receptor	Target Info	Antagonist	[530096], [551730]
KEGG Pathway	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	Serotonergic synapse
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	5HT1 type receptor mediated signaling pathway
Reactome	Serotonin receptors
	G alpha (i) signalling events
WikiPathways	Serotonin HTR1 Group and FOS Pathway
	Monoamine GPCRs
	GPCRs, Class A Rhodopsin-like
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 547616	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017898)
Ref 530096	N-methyl-3H3AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy. J Pharmacol Exp Ther. 2009 Jul;330(1):342-51.
Ref 551730	Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.